S-1: cbdMD Secures $20M Equity Line, Addresses Dilution Concerns

cbdMD, Inc. has entered into a $20 million equity line of credit agreement with C/M Capital Master Fund, LP to bolster working capital and general corporate purposes, while navigating significant dilution risks.

Summary

• cbdMD, Inc. (YCBD) has entered into a Securities Purchase Agreement with C/M Capital Master Fund, LP for an equity line of credit of up to $20,000,000.
• The agreement allows cbdMD to sell shares of its common stock to C/M Capital Master Fund, LP at its discretion over a 36-month period from the Commencement Date.
• The purchase price for these shares will be at a discount, specifically the lesser of 95% of the lowest sale price on the preceding day or the 5-day VWAP.
• In consideration for the agreement, cbdMD will issue up to 80,000 Commitment Shares to the investor, with 40,000 shares already issued.
• The total number of shares registered for resale under this prospectus is 3,234,000, comprising 3,154,000 Purchase Shares and 80,000 Commitment Shares.
• The company is subject to an Exchange Cap of 19.99% of outstanding common stock (approximately 1,790,986 shares) unless shareholder approval is obtained or shares are sold at or above the Base Price of $1.346.
• The investor is prohibited from beneficially owning more than 4.99% of outstanding common stock (can be increased to 9.99% with 61 days notice).
• Proceeds from the sale of shares will be used for working capital and general corporate purposes.
• The company's auditors have issued a going concern audit opinion for fiscal years ended September 30, 2025, and 2024.
• Management reported reducing GAAP operating loss from $3.3 million in fiscal 2024 to $2.1 million in fiscal 2025, while maintaining revenue.
• The company successfully converted Series A Convertible Preferred Stock and accrued dividends into approximately 91% of outstanding common stock in April 2025, regaining NYSE American listing compliance.
• The Oasis brand is growing but is currently an earnings drag due to scaling investments.
• cbdMD has identified nearly $200,000 in corporate overhead savings for early 2026.
• The company issued Series B Convertible Preferred Stock for $1.7 million in September 2025 and Series C Convertible Preferred Stock for $2.25 million in December 2025.

Sentiment

Score: 3

Explanation: While the company has secured an equity line and reduced operating losses, the 'going concern' audit opinion, significant dilution risk from the equity line, and the 'significant threat' from federal regulatory action in the hemp industry indicate a highly challenging financial and operational environment. The capital raises are necessary but come with substantial costs and risks.

Positives

• Secured an equity line of credit for up to $20,000,000, providing a potential source of capital for working capital and general corporate purposes.
• Reduced GAAP operating loss from $3.3 million in fiscal 2024 to $2.1 million in fiscal 2025.
• Successfully cleaned up the capital structure by converting Series A Convertible Preferred Stock and accrued dividends, leading to regaining NYSE American listing compliance.
• The Oasis brand is showing momentum with sequential and year-over-year revenue increases, adding distributors, and improving sell-through.
• Identified nearly $200,000 in corporate overhead savings to be implemented in early 2026.

Negatives

• The purchase price for shares sold to the investor will be at a discount (e.g., 95% of market price), potentially causing downward pressure on the stock price.
• The equity line of credit carries a substantial risk of dilution for existing shareholders.
• The company's auditors have issued a going concern audit opinion for fiscal years ended September 30, 2025, and 2024, indicating substantial doubt about its ability to continue as a going concern.
• The Oasis brand is currently an earnings drag due to investment in scaling.
• Federal action in November 2025 poses a significant threat to the hemp industry and the company's revenue bases.
• The company may not have access to the full $20,000,000 available under the Purchase Agreement if conditions are not met or if the investor faces liquidity issues.

Risks

• It is not possible to predict the actual number of shares to be sold under the Purchase Agreement, the gross proceeds, or the dilution from those sales.
• The company may not have access to the full amount available under the Purchase Agreement, which could necessitate more costly and time-consuming financing.
• The Selling Shareholder will pay less than the then-prevailing market price for common stock (e.g., 5% or greater discount), which could cause the price of common stock to decline due to immediate resale.
• Investors buying shares from the Selling Shareholder at different times will likely pay different prices and experience different levels of dilution.
• Future resales and/or issuances of common stock, or the perception of such sales, may cause the market price of shares to drop significantly.
• The company may use proceeds from sales in ways with which shareholders may not agree or that may not yield a significant return.
• If the company does not raise debt or equity capital, it may not be able to pay all contractual obligations.
• The company's auditors have issued a going concern audit opinion, indicating substantial doubt about its ability to continue as a going concern.
• The stock price may be volatile due to factors beyond the company's control, including failure to increase revenue, meet guidance, cybersecurity breaches, loss of customers, loss of key employees, large stock sales, adverse court rulings, regulatory changes, market valuations, short selling, financing announcements, and macroeconomic factors.
• Failure to satisfy NYSE American continued listing standards may result in de-listing.

Future Outlook

The company expects to continue building momentum in its direct-to-consumer business and wholesale operations, with additional Oasis distribution. It anticipates benefits from scale and reduced overhead expenses for the Oasis brand in the first fiscal quarter of 2026. The company also plans to implement nearly $200,000 in corporate overhead savings during early 2026. However, federal regulatory action in November 2025 poses a significant threat to the hemp industry and the company's revenue bases.

Management Comments

• Managements efforts to drive shareholder value during 2025 were focused in two areas: (i) deliver positive earnings through a combination of optimizing our product portfolio, rationalizing our cost structure, and growing revenue and (ii) simplifying our capital structure.
• During fiscal 2025, we made progress on strengthening the business. We were able to essentially maintain our revenue base and we continued to reduce our GAAP operating loss from a $3.3 million loss during fiscal 2024 to $2.1 million during fiscal 2025.
• We accomplished this while still focusing on disciplined cost control, rebuilding our marketing team and launching into the exciting hemp derived THC beverage category with our brand Oasis.
• During fiscal 2025, we were successful in cleaning up our capital structure and, at our annual meeting in April 2025, we secured sufficient votes to convert our Series A Convertible Preferred and outstanding accrued preferred dividends into approximately 91% of the Companys outstanding common stock.
• This vote was critical to regaining compliance with NYSE American continued listing standards and maintaining our NYSE American listing as well as make the Company more attractive for merger and acquisition activity.
• We are now back in compliance with the NYSE Americans continued listing standards and our non-compliance status has been removed.
• During the fiscal fourth quarter of 2025, the Company continued to make progress on building momentum with sequential and year-over-year increase in revenue.
• We continue to make progress with our Oasis brand, which continues to grow quarterly as we added distributors and improved our sell-through at retailers.
• To date, Oasis has been a P&L earnings drag on the Company as we invest in a scaling, high-growth category.
• We made changes during the first fiscal quarter of 2026 to reduce certain Oasis brand overhead expenses and add sales staff and we are starting to see some benefits of scale as revenues continue to grow.
• cbdMD believes trends from late 2025 are continuing in the first quarter of 2026. We are seeing momentum in our direct-to-consumer business, wholesale is trending up and we added additional Oasis distribution during the quarter.
• In addition, we have identified nearly $200,000 in corporate overhead savings that will be implemented during early 2026 with insurance renewals and professional fees leading the way.
• During calendar 2025, we have faced a notable uptick in both state and federal regulatory activity. While most of the state level action to restrict the hemp category occurred, the industry built sufficient support to limit many restrictions on our industry. Unfortunately, federal action in November 2025 poses a significant threat to the industry and our revenue bases.

Industry Context

The company operates in the CBD and functional mushroom markets, which are subject to evolving regulatory landscapes. The filing highlights a "notable uptick in both state and federal regulatory activity" in calendar 2025, with federal action in November 2025 posing a "significant threat" to the hemp industry and the company's revenue bases. This indicates a challenging and uncertain regulatory environment that could impact growth and operational stability for companies in this sector. The company's expansion into hemp-derived THC beverages (Oasis) and functional mushrooms (ATRx Labs) reflects diversification efforts within the broader wellness and natural products industry.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Existing shareholders face substantial dilution due to the equity line of credit and discounted share sales. The value of their shares may decline. They will also be asked to approve the waiver of the Exchange Cap.
• Employees/Management: Executive compensation for the CEO/CFO has increased, and new restricted stock awards are planned, subject to shareholder approval.
• Creditors: The "going concern" opinion indicates increased risk for creditors. The capital raises (equity line, Series B, Series C) could improve liquidity, but the overall financial health remains a concern.
• Investors (C/M Capital Master Fund, LP): The investor gains the right to purchase shares at a discount and receives Commitment Shares, but also takes on the risk associated with the company's financial condition and market volatility.

Next Steps

• File a Current Report on Form 8-K relating to the transactions contemplated by the Securities Purchase Agreement and Registration Rights Agreement.
• File a new registration statement on Form S-1 covering the resale of Purchase Shares and Commitment Shares within 30 calendar days from the Execution Date (December 15, 2025).
• Hold a meeting of stockholders by March 31, 2026, to seek approval of a waiver of the Exchange Cap and, if needed, an increase in authorized common stock.
• If stockholder approval for the Exchange Cap is not obtained by the deadline, cause additional stockholder meetings to be held semi-annually thereafter until approval is obtained.
• The company will continue to implement changes to reduce Oasis brand overhead expenses and add sales staff in Q1 2026.
• Implement identified corporate overhead savings of nearly $200,000 during early 2026.

Key Dates

Recommendation

The company's auditors have issued a going concern opinion, indicating significant financial distress. While the equity line of credit provides access to capital, it comes with substantial dilution risk for existing shareholders, as shares will be sold at a discount to market price. Furthermore, federal regulatory action poses a "significant threat" to the company's core business. These factors, combined with the potential for stock price volatility and the need for ongoing capital raises (Series B, Series C, and the new equity line), suggest a highly precarious investment, making it a strong sell for seasoned investors.

Keywords

cbdMD, YCBD, Equity Line of Credit, Common Stock, Dilution, SEC Filing, Capital Raise, Going Concern, Hemp Industry, CBD, Cannabidiol, NYSE American, Financial Health, Corporate Governance, Risk Factors, C/M Capital Master Fund, Securities Purchase Agreement, Registration Statement S-1